AstraZeneca’s Fasenra (benralizumab) injected drug cuts the size of nasal polyps and nasal blockage in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). The company announced top ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback